Analyst Ratings For Bioline RX (NASDAQ:BLRX)
Today, HC Wainwright reiterated its Buy rating on Bioline RX (NASDAQ:BLRX) with a price target of $4.00.
Some recent analyst ratings include
- 3/6/2018-HC Wainwright Reiterated Rating of Buy.
- 12/21/2017-Oppenheimer initiated coverage with a Buy rating.
- 2/13/2017-Rodman & Renshaw initiated coverage with a Buy rating.
Recent Trading Activity for Bioline RX (NASDAQ:BLRX)
Shares of Bioline RX closed the previous trading session at with 1.0099999904632568 shares trading hands.